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Conventional manufacturing methods for oral administration forms are adapted to produce large batches of tablets
of identical dosage form (same geometry, size and dosage). These methods are inflexible or not economically
feasible to be adapted to the production of small, customized batches, either for special groups of patients or special
geometries [1].
In recent decades, additive manufacturing, more commonly known as 3D printing (3DP), has become a
promising tool in many production processes, including the medical and pharmaceutical industry. This technology
enables on demand, layer-by-layer fabrication of 3D objects of almost any shape and size based on digital designs.
In this way, it is easy to manufacture individualized objects, custom made [2]. This technology allows precise
doses to be deposited, based on the initial ‘ink’ concentration and the physical dimensions of the formulation [3].
Pharmaceutical industry interest in 3DP has grown continuously since the US FDA approval of a 3D-printed drug
in August 2015 [4].
The potential of 3DP in the pharmaceutical field is enormous. 3DP simplifies the traditional manufacturing
process by reducing the usual steps (grinding, wet granulation, dry granulation, compression, coating, etc.) and
allows for the variation of the sizes and geometry of the tablets; and it also allows the combination of materials of
different nature [5]. Although this type of production cannot match the speed (it is 60-times slower) or the costs of
large-scale production methods, the 3D printers’ ability to produce different parts with enormous flexibility would
allow the manufacture of pharmaceutical forms on demand, that is, to individualize drugs according to the needs
of each patient, as well as it would allow combining different active ingredients (multidose tablets) [6].
Technologies in 3DP of medicines
It should be noted that various 3DP methods have been developed and patented for the production of medicines.
The most used in obtaining medicines are classified into:
• Inkjet printing systems: powder bed printing;
• Extrusion printing systems: fused deposition model (FDM) and pressure-assisted microsyringe;
• Radiation printing systems: stereolithography and sintering selective laser.
The rationale behind 3DP is always the same: material is added layer by layer until the desired 3D shape is
obtained. However, each of the different methods mentioned uses a completely different 3D printer and presents
particular characteristics with advantages and disadvantages when used in in the production of pharmaceutical
systems (Table 1).
Among the main disadvantages, it is possible to mention the use of materials that have not yet been approved for
human use, the use of water or other solvents that must be removed later, the use of very high temperatures, the
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Table 1. Overview of 3D printing methods for the production of pharmaceuticals.
Classification Printing method Process Ink Advantages Disadvantages Ref.
Inkjet PBP A binder solution or
suspension is deposited
on a bed of powders
The binders are the same as
those used in wet granulation
(e.g., PVP)
Powder bed is composed of




and polyol such as lactose or
mannitol
The API can be present in the






• Possibility of cross
contamination from the use of
powders
• Requires prior preparation:
flow control,
selection/preparation of the
binder). High control of powder
flow level and moisture content
• Requires postprocessing: print
drying, slow solidification times
and shrinkage of bonded
material
[7,8]
Extrusion FDM A solid filament is
extruded through a
high-temperature
nozzle where it is
heated to a semi-liquid
state to be deposited
Drug-loaded thermoplastic
polymer filaments. PVA is the
most widely used material.
Pharmaceutical HME technique is





• Does not use
solvents (avoids
drying time)
• Use of high temperatures
(around 170◦C) which is
inconvenient for heat sensitive
APIs





in a syringe is extruded











• To achieve the proper viscosity,
solvents are used that require a
prolonged drying process
immediately after printing
(from 24 to 48 h)
• Low drug carrying capacity
• Slow process
[8]
Radiation SLA A laser of radiation of
a certain wavelength
falls on a liquid resin
Photoactive resins, which are
capable of polymerizing in
contact with UV or visible light







• Carcinogenic risk of the
photopolymerization material
restricts its implementation and
requires washing processes that
ensure the complete removal of
the photocurable film
[11]
SLS A thermal laser draws
a specific pattern on a




Powder bed with photoactive
resins (polystyrene, ceramic
materials, glass, nylon and




• It uses powders that require
high temperatures and high
energy lasers to be sintered
• Requires postprocessing: dust
must be removed after printing
[12,13]
API: Active pharmaceutical ingredient; FDM: Fused deposition model; HME: Hot melt extrusion; PAM: Pressure-assisted microsyringe; PBP: Powder bed printing; PVA: Polyvinyl alco-
hol; SLA: Stereolithography; SLS: Sintering selective laser.
low drug loading capacity and the need for long operations before or after printing, such as loading thermoplastic
filaments, formulating gels, controlling powder flow or drying forms.
Considering the different disadvantages of these methods, which thwart their use in pharmaceutical systems,
especially if one thinks of elaboration in places such as pharmacies and hospitals, a new printing method was
developed, which we have called melting solidification printing process (MESO-PP) [14].
New proposed technology: MESO-PP
The MESO-PP makes use of fusion/solidification techniques and adapts them to work along with 3D technology
(Figure 1). This technique constitutes a simple, flexible and economical method. It is adaptable to small batches of
drug manufacturing that allows it to be adapted to special groups of patients or special geometries.
The MESO-PP procedure uses materials that have a melting temperature in the range of 40 to 60◦C. Among these
excipients, we can mention certain lipids such as gelucire or hydrophilic polymers such as polyethylene glycol,
which mixed with other components or by themselves form what we call ‘inks’. These inks are mixed in a solid
state with one or more active ingredients (drugs) to make a premixed solid product (PSM), which can be used
immediately or be stored in a stable form.
At the time of printing, the whole solid mixture is heated to a temperature above the melting point of the ink,
with continuous agitation greater than 150 RPM. As a result of the heating, the ink melts and the active ingredient
is incorporated in suspended or dissolved form.
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Figure 1. A graphical overview of the MESO-PP process.
API: Active pharmaceutical ingredient.
Once the drug is incorporated, the mixture is ready to be heated (melted), extruded and deposited in a controlled
manner on a printing surface (which can be cooled) following the pattern designed by computer to create a 3D
image from the layer to layer material aggregate.
This process so far has several advantages over those previously mentioned [15]:
• It does not use water or any other solvent, which improves the stability of the drugs and reduces costs related to
the removal of the solvent (drying process);
• It allows to obtain solid drugs without needing to use high temperatures with the consequent improvement in
stability (it allows using the technique with thermosensitive drugs) and costs reduction due to the lower heat
necessary;
• It uses safe materials, widely used in pharmaceutical technology (e.g., polymers and lipids) with the regulatory
advantage that this brings;
• It does not require previous operations or processes (such as the manufacture of filaments or inks as is the case
with FDM) with the consequent advantage of versatility and potential use in the manufacture of medicines on
a reduced scale (pharmacies or hospitals);
• It is a versatile method that allows the incorporation of the asset(s) prior to printing and can be carried out in a
single stage;
• The printers used for this method are portable, inexpensive and relatively simple to operate, making them
eligible for deployment in pharmacies and points of patient care.
A new trend?
The 3DP of medicines is not only a new technology, it constitutes a technological leap and a paradigm shift
for pharmaceutical technology. The medicinal specialties that we know today are prepared and packaged by the
pharmaceutical industry for distribution and sale. 3DP could add to this concept a new type of custom medicinal
specialty. These specialties would be configured in a digital design and they would be ready to be prepared at the
points of patient care using previously validated processes and inks. For this to be possible, it would be necessary to
have automatic, versatile and sufficiently robust methods and equipment so as not to require previous elaboration
stages or postprocessing stages.
Until the appearance of MESO-PP, only the FDM technique fulfilled the requirements for decentralized and
tailor-made production. This is probably one of the reasons why FDM leads the number of publications related to
3DP of medicines. The new technique patented by the National University of Cordoba (Argentina), complements
FDM, providing even more and new advantages that could make it the method of choice for customizing medication.
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